ArticleInflammatory bowel diseases2022
Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study.
Jurij Hanzel et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
14 papers cite it
this papertrialcites it